RNA-guided STAT3 modification fine tunes the epigenetic and epitranscriptomic regulation of CD4 + T helper cell differentiation during non-small cell lung cancer (NSCLC)
Medical Oncology · 27.12.2025 · 43 (2)
DOI: 10.1007/s12032-025-03230-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Oncology, online erschienen am 27.12.2025. Verfasst von Roshni Bibi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu, 603203, India. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Epigenesis, Genetic. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Ministry of Tribal Affairs, Govt. of India, Indian Council of Medical Research.
Abstract (Originalsprache)
The accurate control of immune responses in the tumor microenvironment is crucial for augmenting anti-cancer immunity. This work examined the function of STAT3 in modulating epigenetic and epitranscriptomic pathways during the differentiation of CD4 + T helper cells in non-small cell lung cancer (NSCLC). Employing CRISPR/Cas9 genome editing, STAT3 was specifically eliminated in CD4+T cells derived from NSCLC patients. Functional investigations demonstrated that the reduction of STAT3 markedly enhanced the production of T helper 1 (TH1) cytokines, notably IFN-γ, while concurrently diminishing immunosuppressive signaling. Epigenetic analysis revealed significant modifications in DNA and RNA methylation patterns, along with heightened R-loop formation-alterations linked to augmented transcriptional activity of anti-tumor immune genes. Moreover, STAT3-deficient CD4+T cells demonstrated an enhanced ability to activate cytotoxic T lymphocytes, facilitating the targeted eradication of tumor cells. All of these effects together made the NSCLC microenvironment's immune system better at fighting cancer. Our results identify STAT3 as a crucial regulator of the genetic and epigenetic frameworks that influence T cell functionality in lung cancer. By combining RNA-guided genome editing with immune functional tests, we show that blocking STAT3 in a specific way could bring back strong anti-tumor immunity. This research underscores the therapeutic potential of STAT3-targeted therapies, presenting an innovative approach to alter T cell destiny and improve immune-mediated tumor eradication in non-small cell lung cancer (NSCLC). These methods could lead to the next generation of immunotherapies that improve clinical outcomes by fine-tuning both epigenetic and epitranscriptomic circuits.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu, 603203, India.
- Centre for Clinical Pharmacology, SRM Medical College Hospital and Research Centre, Kattankulathur, Chennai, Tamil Nadu, 603203, India.
- Department of Biotechnology, School of Bioengineering, SRM Institute of Science and Technology, Kattankulathur, Chennai, Tamil Nadu, 603203, India. koustavm@srmist.edu.in.
Förderung
- Ministry of Tribal Affairs, Govt. of India
- Indian Council of Medical Research
Zitieren
APA
Bibi, R., George, M., & Sarkar, K. (2025). RNA-guided STAT3 modification fine tunes the epigenetic and epitranscriptomic regulation of CD4 + T helper cell differentiation during non-small cell lung cancer (NSCLC). Medical Oncology, 43(2). https://doi.org/10.1007/s12032-025-03230-1
Vancouver
Bibi R, George M, Sarkar K. RNA-guided STAT3 modification fine tunes the epigenetic and epitranscriptomic regulation of CD4 + T helper cell differentiation during non-small cell lung cancer (NSCLC). Medical Oncology. 2025;43(2). doi:10.1007/s12032-025-03230-1
BibTeX
@article{Bibi2025,
author = {Bibi, Roshni and George, Melvin and Sarkar, Koustav},
title = {RNA-guided STAT3 modification fine tunes the epigenetic and epitranscriptomic regulation of CD4 + T helper cell differentiation during non-small cell lung cancer (NSCLC)},
journal = {Medical Oncology},
year = {2025},
volume = {43},
number = {2},
doi = {10.1007/s12032-025-03230-1}
}
EUVIMED